Moderna jumps as call buying resurfaces after EU panel backs flu/COVID combo shot
Moderna shares are higher on April 13, 2026 as traders point to renewed bullish positioning in the options market, following recent regulatory momentum for its flu/COVID combo vaccine. The stock is up about 3.75% to $51.92 amid elevated call activity and continued focus on the upcoming EU decision timeline for mCOMBRIAX (mRNA-1083).
1. What’s moving the stock
Moderna (MRNA) is trading higher Monday, April 13, 2026, as the name shows signs of renewed risk-on sentiment tied to options-market positioning. Market chatter centers on elevated call activity and “unusual options” interest around the ticker, which can amplify short-term price moves when liquidity is thinner or when traders reposition quickly into a volatile biotech tape. (benzinga.com)
2. The fundamental backdrop traders are leaning on
The bullish bias is landing on top of a key recent catalyst: the European Medicines Agency’s CHMP issued a positive opinion recommending marketing authorization for mCOMBRIAX (mRNA-1083), Moderna’s combined influenza and COVID-19 vaccine for adults 50 and older. The positive CHMP opinion is typically a major step toward a European Commission decision, keeping investor attention on a potential commercial inflection for Moderna’s respiratory portfolio ahead of the 2026/27 season. (moderna2022rd.q4web.com)
3. Why it matters now
With Moderna still in a post-pandemic transition, incremental signs of product portfolio expansion—especially combination respiratory vaccines—can shift near-term sentiment quickly, particularly when paired with momentum-driven trading and options flow. Today’s move looks consistent with that setup: regulatory progress remains a recent anchor for the bull case, while options activity and positioning appear to be providing the day’s immediate fuel. (nasdaq.com)